| Name | PF-05175157 |
| Description | PF 05175157 is an inhibitor of acetyl-CoA carboxylase 1 (ACC1) and ACC2 (IC50s = 27, 33, 23.5, and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2, respectively |
| Animal Research | Pharmacokinetics was analyzed after a single oral dose of the compounds (in a 0.5% methyl cellulose suspension) administered to fasted male mice. A dose of 15 mg/kg for PF-05175157 or 100 mg/kg in the case of PF-05206574 and PF-06256254 was analyzed. Antiviral activity in vivo was determined using eight-week-old Swiss albino CD-1 female mice. Animals were treated with PF-05175157 (20 mg/kg) suspended in 1% carboxymethylcellulose by oral gavage twice a day from 1 d before infection with WNV (1 × 10^4 PFU/mouse intraperitoneally) and up to 7 days post-infection. Control mice were treated in parallel with drug vehicle (carboxymethylcellulose). For experiments evaluating the effect of genetic deletion of ACC2 gene on WNV infection, a breeding colony of C57BL/6 ACC2-/- mice was established from two heterozygous Acabtm1Dejs females . Age- and sex-matched eight-week-old ACC2-/- and control wild type (WT) mice were challenged with WNV (1 × 10^4 PFU/animal.). Animals were monitored daily and received water and food ad libitum. |
| In vivo | PF-05175157 induced a reduction of the viral load in serum and kidney in WNV-infected mice, unveiling its therapeutic potential for the treatment of chronic kidney disease associated with persistent WNV infection. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 140 mg/mL (345.26 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.47 mM), Sonication is recommended.
|
| Keywords | PF-05175157 | PF05175157 | PF 05175157 | Inhibitor | inhibit | AcetylCoACarboxylase | Acetyl-CoA Carboxylase | AcetylCoA Carboxylase | ACC, Acetyl Coenzyme A Carboxylase | ACC |
| Inhibitors Related | Alisol A | CMS-121 | Cyhalofop-butyl | Acetyl-CoA Carboxylase-IN-1 | Firsocostat | PF-05221304 | Clethodim | Clodinafop-propargyl | VY-3-135 | Quizalofop-ethyl | TOFA | Tralkoxydim |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Obesity Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
